Valuation: Kinarus Therapeutics Holding AG

Market Cap 4.72M 5.9M 5.06M 4.33M 8.13M 565M 8.29M 55.95M 21.81M 283M 22.17M 21.69M 937M P/E 2022
-0.23x
P/E 2023 -0.01x
Enterprise Value 4.71M 5.89M 5.05M 4.32M 8.12M 564M 8.28M 55.85M 21.77M 283M 22.13M 21.65M 936M EV / Sales 2022
4,318,722x
EV / Sales 2023 -
Free-Float
-
Yield 2022 *
-
Yield 2023 -
Current month+23.39%
Current year+23.39%
3 years 0.9
Extreme 0.895999
35.84
5 years 0.9
Extreme 0.895999
230.27
10 years 0.9
Extreme 0.895999
230.27

Financials

2022 2023
Net sales 3.34 4.18 3.58 3.06 5.75 399.58 5.87 39.58 15.43 200.25 15.68 15.34 662.97 -
Net income -34.73M -43.48M -37.23M -31.87M -59.89M -4.16B -61.06M -412M -161M -2.08B -163M -160M -6.9B -49.38M -61.81M -52.93M -45.31M -85.14M -5.91B -86.82M -586M -228M -2.96B -232M -227M -9.81B
Net Debt 1.66M 2.08M 1.78M 1.52M 2.86M 199M 2.92M 19.67M 7.67M 99.53M 7.79M 7.62M 329M -9K -11.27K -9.65K -8.26K -15.52K -1.08M -15.82K -107K -41.62K -540K -42.3K -41.38K -1.79M
Logo Kinarus Therapeutics Holding AG
Kinarus Therapeutics Holding AG is a Switzerland-based Company that operates as a biopharmaceutical industry engaged in diseases treatment. The Company conducts its work within clinical-stage area and its activities include discovery, examination and development of medicines that are intended for the treatment of viral, respiratory, and ophthalmic diseases. Kinraus therapeutic drug is patent protected KIN001 which is a combination of pamapimod and pioglitazone. KIN0001 offers oral, long-term treatment of diseases with severe impact on the comfort of living.
Employees
-
Sector
-
Date Price Change Volume
26-08-21 CHF 19.90 0.00% 2
26-08-20 CHF 19.90 -0.25% 783
26-08-19 CHF 19.95 -0.25% 1,165
26-08-18 CHF 20.00 +10.50% 1,697
26-08-17 CHF 18.10 +0.56% 46
  1. Stock Market
  2. Stocks
  3. CURE Stock